000			05664nam a22003975i 4500
001			80241
003			ES-MaUEC
005			20230202102508.0
007			cr nn 008mamaa
008			140110s2014 xxu| s |||| 0|eng d
020			_a9781461491354
024	7		_a10.1007/978-1-4614-9135-4 _2doi
050		4	_aRS431 _b.H363 2014
245	1	0	_aHandbook of Anticancer Pharmacokinetics and Pharmacodynamics _cedited by Michelle A. Rudek, Cindy H. Chau, William D. Figg, Howard L. McLeod.
250			_a2nd ed. 2014.
260			_aNew York _bSpringer International Publishing _c2014
300			_a1 recurso en línea (IX, 836 p.) _b145 ilustraciones, 46 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCancer Drug Discovery and Development _x2196-9906
505	0		_a1. Molecular Targets -- 2. Preclinical Screening for New Anticancer Agents -- 3. Natural Product Screening -- 4. Defining the Starting Dose: Should it be mg/kg, mg/m2 or Fixed? -- 5. Phase 0 Trials in Oncology -- 6. Phase I Trials in Oncology - Design and Endpoints -- 7. Quantitative Analytical Methods: Development and Clinical Considerations -- 8. Validation and Control of Bioanalytical Methods -- 9. Anti-Cancer Clinical Pharmacology Overview -- 10. Pharmacokinetic Modeling -- 11. Pharmacometrics -- 12. Pharmacodynamic Modeling -- 13. Protein Binding -- 14. Metabolism (Non-CyP Enzymes) -- 15. Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms -- 16. Cytochrome P450 -- 17. Polymorphisms in Genes of Drug Targets and Metabolism -- 18. DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance -- 19. Drug Interactions -- 20. ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition -- 21. Solute carriers -- 22. High Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics -- 23. Intrathecal Administration -- 24. Microdialysis -- 25. Regional Drug Delivery for Inoperable Pulmonary Malignancies -- 26. Blood-Brain-Barrier & CNS Malignancy -- 27. Radiation and Altering Clinical Pharmacology -- 28. Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment -- 29. Recombinant Immunotoxins -- 30. Monoclonal Antibodies -- 31. Clinical Pharmacology in Pediatrics -- 32. Clinical Pharmacology in the Elderly -- 33. Organ Dysfunction Trials:¡ckground, Historical Barriers, Progress in Overcoming Barriers and Suggestions for Future Trials -- 34. Drug Formulations: How this Affects Anticancer Drug Pharmacokinetics and Pharmacodynamics -- 35. Nanotechnology in Cancer -- 36. Imaging in Drug Development -- 37. Exposure-Response Relationship of Anticancer Agents: Application in Drug Development and Drug Label -- 38. The Role of Phase III Trials in Modern Drug Development -- 39. Clinical Trial Designs for Approval of New Anticancer Agents -- 40. Clinical Pharmacogenetics.
520			_aThere are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer. Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs. Road map to anticancer drug development from discovery to NDA submission Discussion of molecular targets and preclinical screening Development and validation of bioanalytical methods Chapters on clinical trial design and phase 0, I, II, III clinical trials Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents Review of the drug development process from both laboratory and clinical perspectives New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development.
942			_2lcc _cLE
988			_aEBSPRINGER
650		7	_aFarmacia _0LocalW _2embne _9137891
650		7	_aFarmacia _2embne _9137891
700	1		_aRudek, Michelle A _eeditor literario _988262 _0Local
700	1		_aChau, Cindy H. _eeditor literario _0Local _988263
700	1		_aFigg, William D _eeditor literario _939106 _0comprobar BNE20051801437
700	1		_aMcLeod, Howard L _eeditor literario _988264 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-9135-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12879940 _b10-10-17 _c11-11-15
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _gxxu _h0
945			_aRS431 .H363 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11559767 _z06-04-17
999			_c80241 _d80241 _x1